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Abstract 
The best available surgical strategy in the treatment of resectable esophago-gastric junctional 
(EGJ) cancer is a controversial topic. In this review we evaluate the current literature and 
scientific evidence examining the surgical treatment of locally advanced EGJ cancer by 
comparing esophagectomy with gastrectomy, transhiatal with transthoracic esophagectomy, 
minimally invasive with open esophagectomy, and less extensive with more extensive 
lymphadenectomy. We also assess endoscopic procedures increasingly used for early EGJ 
cancer.  
The current evidence does not favor any of the techniques over the others in terms of 
oncological outcomes. Health-related quality of life may be better following gastrectomy 
compared to esophagectomy. Minimally invasive procedures might be less prone to surgical 
complications. Endoscopic techniques are safe and effective alternatives for early-stage EGJ 
cancer in the short term, but surgical treatment is the mainstay in fit patients due to the risk of 
lymph node metastasis. Any benefit of lymphadenectomy extending beyond local or regional 
nodes is uncertain.  
This review demonstrates the great need for well-designed clinical studies to improve the 
knowledge in how to optimize and standardize the surgical treatment of EGJ cancer.  
 
Keywords: Esophago-gastric junctional cancer, cardia cancer, gastrectomy, esophagectomy, 
lymphadenectomy, surgery. 
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1. Introduction 
Esophageal cancer is the 8th most common cancer and the 6th most common cause of cancer 
death worldwide, while gastric cancer is the 5th most common type of cancer and 2nd most 
common cause of cancer death.1 A cancer located in the distal esophagus or proximal stomach 
is typically referred to as an esophago-gastric junctional (EGJ) cancer.2 The main risk factors 
for adenocarcinoma of the EGJ are partly shared with those of esophageal adenocarcinoma, 
i.e. gastroesophageal reflux disease, obesity, and tobacco smoking,3-7 and partly shared with 
those of gastric adenocarcinoma, i.e. Helicobacter pylori infection and dietary factors.8, 9 The 
incidence of EGJ cancer has increased along with esophageal adenocarcinoma in Europe.10 
For gastric cancer, Helicobacter pylori-infection is the main risk factor and it seems to 
increase the risk in a subgroup of EGJ cancer,8, 11 while weaker risk factors include tobacco 
smoking and dietary factors, i.e. salty, smoked, or poorly preserved foods.12, 13 Both 
esophageal and gastric cancers are associated with a diet low in fruit and vegetables and low 
socioeconomic status.4, 6, 12, 13 Assessment of prevalent risk factors for either esophageal or 
gastric cancer can help in distinguishing between the origin of EGJ cancer. 8, 9 
Surgery, often after completion of neoadjuvant therapy, is the cornerstone of curatively 
intended treatment of EGJ cancer. The 5-year survival following surgery for EGJ cancer is in 
the range of 25-40%.14, 15 Even among patients with a localized (resectable) tumor who are fit 
and therefore eligible for surgery, the majority of operated patients die from recurrence of the 
EGJ cancer.16, 17 The postoperative prognosis is closely related to tumor stage at the time of 
surgery, i.e. after neoadjuvant therapy, particularly with lymph nodal status.18, 19 The addition 
of neoadjuvant chemotherapy or chemoradiotherapy, centralization of surgical treatment, 
improvements in perioperative care, as well as more accurate patient selection following 
developments in imaging techniques and involvement of a multi-disciplinary team, have all 
had positive effects on the EGJ cancer prognosis following surgery.20, 21 Yet, the optimal 
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surgical strategy for these tumors remains controversial. The lack of consensus regarding the 
definition of EGJ cancer and the difficulties in assessing the exact origin of these tumors 
contribute to this controversy.22 In this review, we evaluate the existing evidence and 
rationale for various surgical strategies in the surgical treatment of adenocarcinoma of the 
EGJ. 
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2. Tumor classification 
There are several challenges to the classification of cancers in the EGJ. The EGJ itself is often 
difficult to define. The squamocolumnar junction, also called the Z-line, is one potential 
anatomical basis for the definition,23 but in the presence of a columnar-lined esophagus 
(Barrett’s esophagus), the Z-line shifts proximally, which is misleading.24 Therefore, the 
location of the junction is better defined by the proximal margin of the gastric folds, where 
the tubular esophagus shifts to the sac-shaped stomach, although gastric folds can be obscured 
by hiatal hernias. Gastric inflation during endoscopy, however, can cause normal gastric folds 
to temporarily disappear, making this landmark less clear.25 Large tumors are often difficult to 
evaluate in relation to any adjacent anatomical landmarks. There is no way to macroscopically 
assess the distal border of the gastric cardia, as the parietal cells cannot be visualized 
endoscopically.26 Examination of biopsy specimens can also be problematic, because cardiac 
mucosa can also be found in the distal esophagus and are not necessarily found more than 
3mm below the squamocolumnar junction in the anatomical gastric cardia.27 If the mucosa 
below the tumor is sampled, the biopsy specimen showing healthy gastric mucosa suggests 
esophageal etiology of the tumor, while an inflamed mucosa indicates a gastric origin. 28-30 
The adenocarcinomas of the EGJ are often classified according to the Siewert classification, 
which is based on the macroscopic location of the epicenter of the tumor in relation to the 
EGJ.2 Cancers occurring 1-5cm above the EGJ represent Siewert type I, cancers within 1cm 
above and 2cm below the EGJ are type II, and cancers 2-5cm below the EGJ are type III 
cancers. Cancers more proximal than 5cm above the EGJ are classified as esophageal cancers 
and those more distal than 5cm below the EGJ are labelled distal (or non-cardia) gastric 
cancers.2 In the current (7th) edition of the tumor staging manual (TNM), EGJ cancers are 
staged as esophageal cancer when the tumor extends to the esophagus and as gastric cancer 
when no esophageal extension is visible. Thus, EGJ cancers of Siewert type I and II are 
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staged using the TNM system for esophageal cancer, while Siewert type III cancers are staged 
together with gastric cancer (Figure 1).31 However, the optimal surgical treatment of each of 
the Siewert type I, II and III cancers remains controversial, and the differentiation between 
these types is often difficult and arbitrary in clinical practice.  
The distribution of the premalignant metaplasia Barrett's esophagus indicates differences in 
the etiology of Siewert type I-III tumors and when detected it can facilitate the Siewert 
categorization. Barrett’s esophagus is typically present in Siewert type I tumors, while this 
prevalence is only 5.6% in type II and <1% in type III tumors.7 The male predominance is 
also higher (10.7:1) in type I tumors compared to type II (4.9:1) and type III tumors (2.2:1).7 
These data indicate that type I tumors are esophageal adenocarcinomas, type III tumors are 
gastric adenocarcinomas, while type II tumors represent a mixture of these. If this is the case, 
the EGJ does not constitute a separate anatomic entity. 
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Figure 1. The Siewert classification of esophago-gastric junctional (EGJ) cancers. In the 
WHO classification cancers extending into the esophagus or EGJ are staged as esophageal 
cancer and the rest as gastric cancer. The EGJ itself can be defined by the location of the Z-
line or better by the proximal margin of the gastric folds. 
 
3. Surgical approaches for esophago-gastric junctional tumors 
Regardless of the surgical approach, complete removal of the primary tumor is of highest 
prognostic relevance, regardless of the tumor stage.23 Moreover, better results in both the 
short- and long term are achieved in high-volume centers in general, and by high-volume 
surgeons in particular.32-36 Another potentially important, but controversial factor is the 
surgical approach, which is discussed in more detail below. Five questions addressing key 
aspects of the surgical approach for EJG cancer are evaluated in turn.   
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3.1. Esophagectomy or gastrectomy? 
Esophagectomy for EGJ cancer is usually performed using a transthoracic (more common) or 
a transhiatal approach, and includes resection of the proximal stomach (Figure 2A). 
Transthoracic esophagectomy is done using laparotomy and thoracotomy, and sometimes 
cervical incision, allowing exposure to the entire mediastinum. Gastrointestinal continuity is 
preserved by an intrathoracic anastomosis (Ivor Lewis approach) or cervical anastomosis 
(McKeown modification includes cervical incision).23 37 20, 38 Transhiatal esophagectomy is 
performed through laparotomy and cervical incision, without thoracotomy. The diaphragmatic 
hiatus is opened anteriorly, allowing access to the lower posterior mediastinum. A narrow 
gastric tube following the great curvature or colon or jejunal interposition is used to replace 
the resected esophagus and proximal stomach for both approaches.7, 39, 40 
Gastrectomy for EGJ cancer includes removal of the entire stomach and the distal part of the 
esophagus via a laparotomy, where the diaphragm is opened (Figure 2B). The anastomosis is 
usually placed in the distal part of the chest. The reconstruction is typically an esophago-
jejunostomy with a Roux-en-Y reconstruction.23 
Most EGJ cancers of Siewert type I and II are surgically managed by esophagectomy, while 
total gastrectomy is often applied when the tumor is confined to the stomach (type III).22 
However, in clinical practice, the exact origin of EGJ tumors can sometimes be hard to define, 
which complicates the choice between gastrectomy and esophagectomy.28  
A recent systematic review based on ten studies compared outcomes following 
esophagectomy (total n=1,780) with extended gastrectomy (total n=1,437) in EGJ cancers, 
and found no differences in overall survival, early postoperative mortality or morbidity, 
radical resection rate, or tumor recurrence.16 The results were similar in an analysis restricted 
to Siewert II type tumors only (n=301). However, the studies included in the review were so 
	 																																																																																																											
	 	 		 	
8	
heterogeneous that statistical meta-analysis could not be reliably performed.16 Thus, these 
conclusions should be interpreted with caution. A prospective study of 1,602 EGJ cancer 
patients found no difference in a subgroup analysis of survival between esophagectomy and 
gastrectomy in radically resected Siewert type II tumors (n=377).23, 41 A register-based study 
from the United States found no differences in 30-day morbidity or mortality in 214 patients 
who underwent gastrectomy compared to 967 patients who underwent esophagectomy for 
EGJ cancer.42 The Surveillance Epidemiology and End Results (SEER) program database was 
used to compare gastrectomy (n=1,102) with esophagectomy (n=2,714) for EGJ cancer, and 
found no difference in overall mortality (hazard ratio 0.95, 95% confidence interval 0.88-
1.04).42 Similar results were obtained recently in a Dutch retrospective analysis of 1,196 
patients undergoing esophagectomy (n=939) or gastrectomy (n=257) for EGJ cancer.21 The 5-
year survival rates were similar regardless of surgical approach (36% and 33%, 
respectively).21 However, there was a lower incidence of positive circumferential resection 
margins during esophagectomy compared with gastrectomy in type II tumors (n=176, 11% vs. 
29%, respectively, p=0.025).21 
Two small studies have compared health-related quality of life (HRQoL) aspects following 
esophagectomy and gastrectomy in EGJ cancer (including a total of 59 and 31 patients, 
respectively).43, 44 Both studies suggested better HRQoL scores for global quality of life, 
work, leisure and social function, and fatigue, as well as fewer gastrointestinal symptoms 
following gastrectomy. The statistical power was insufficient for subgroup analysis for type II 
tumors only.43, 44  
Taken together, extended esophagectomy and gastrectomy seem to offer similar results in 
terms of surgical complications or long-term oncological outcomes for EGJ cancer. Limited 
evidence available suggests that gastrectomy approach may increase the risk of positive 
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esophageal circumferential resection margins, while gastrectomy seems to be favorable 
regarding HRQoL outcomes. Further research is needed to examine these outcomes.  
 
 
Figure 2. The difference between the resection lines in esophagectomy (left) and gastrectomy 
(right) for esophago-gastric junctional cancer. 
 
3.2. Transhiatal or transthoracic esophagectomy? 
The two main approaches for esophagectomy for EGJ cancer are transthoracic or transhiatal 
resections. These procedures were described above. A randomized clinical trial (RCT) from 
the Netherlands compared transthoracic (n=114) with transhiatal esophagectomy (n=106) 
with type I or II EGJ cancers.45, 46 Transthoracic esophagectomy entailed more perioperative 
morbidity, while the overall 5-year survival was similar for transhiatal and transthoracic 
esophagectomy (34% vs. 36%, respectively).45, 46 A Japanese RCT compared transthoracic 
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(n=85) with transhiatal esophagectomy (n=82) with type II or type III EGJ cancers.47 The 
study was stopped after the interim analysis because transhiatal esophagectomy did not offer 
survival benefit but increased postoperative morbidity.47 In a meta-analysis including eight 
studies (five observational studies and three RCTs) and a total of 1,155 patients (639 operated 
with transthoracic and 516 with transhiatal esophagectomy), transthoracic resection was 
associated with increased risks of 30-day mortality, pulmonary complications, and longer 
hospital stay, while no differences in survival, extent of lymph node dissection, blood loss, 
duration of surgery, anastomotic leaks, or cardiovascular complications were observed.17 A 
recent cohort study from the United Kingdom comparing transhiatal (n=263) and 
transthoracic (n=401) esophagectomy in patients with esophageal or EGJ cancer found no 
differences between these groups regarding resection margin status, complications, length of 
hospital stay, tumor recurrence, or survival.48  
No studies have compared HRQoL in transhiatal esophagectomy and transthoracic 
esophagectomy focusing on EGJ cancers. However, an RCT from the Netherlands found no 
differences in HRQoL following transhiatal esophagectomy and transthoracic esophagectomy 
in patients with esophageal cancer.49 
Taken together, the current evidence does not favor the transthoracic or transhiatal procedure 
over the other, although the transhiatal approach seems to render fewer pulmonary 
complications. Transhiatal esophagectomy may be preferable in type II and III tumors. There 
is, however, a need for large RCTs to clarify whether these approaches differ in terms of long-
term overall survival.  
 
3.3. More or less extensive lymphadenectomy? 
The lymphatic tumor spread differs between the Siewert types of EGJ cancers. According to a 
large observational study from Germany (n=1,602) lymph node metastases occur more 
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frequently in type II (65.2%) and type III (77.8%) cancers, compared to type I cancers 
(51.9%).23 Predominantly paracardial regions and lower posterior mediastinal lymph nodes 
are involved in type I tumors, whereas types II and III tumors are drained predominantly 
towards the coeliac axis and the greater curvature of the stomach. Metastasis in upper 
mediastinal lymph nodes occurs in 15% of type I tumors, but is rare in type II and III 
tumors.23 In type II and III EGJ cancers the incidence of metastasis is more than 10% at the 
lymph node stations of the paracardial region, lesser curvature and coeliac trunk (station 
numbers 1 2, 3, 7, 9, 11p and 19 in the Japanese classification). Especially at lymph node 
stations 1 and 3, the incidence is high in both types of tumors (up to 52.5%).50 The incidence 
of metastasis in the lower perigastric nodes (stations 4d - 6) seems to be especially low in type 
II EGJ cancers.51 Incidence of lymph node metastasis is less than 10% at the coeliac axis, 
around the splenic artery, splenic hilum, and lower mediastinum in type II cancers.52, 53  
A greater number of resected lymph nodes or splenectomy increases the probability of 
complete removal of macroscopic cancer, but also increases the risk of severe postoperative 
complications.54, 55 Routine splenectomy does not offer any survival benefit.53 The lymphatic 
drainage in type I tumors would support a surgical approach allowing both abdominal and 
mediastinal lymphadenectomy. Esophagectomy with proximal gastrectomy might be 
sufficient instead of total gastrectomy and extended lymph node dissection in type II tumors. 
Mediastinal lymphadenectomy may not be needed in type III tumors. 
In a recent systematic review of Siewert type II tumors (n=2,252, 5-year survival reported in 
n=812),56 tumor involvement in para-aortal or other distant nodes indicates very poor 
prognosis, and seven or more metastatic lymph nodes (N3) indicate much worse survival 
(2.0%-17.4%) compared to no lymph node metastasis (up to 82.7%).56 In a multi-center study 
of 2,303 esophageal cancer patients undergoing esophagectomy, dissection of 23 or more 
lymph nodes offered a slight survival benefit compared to less extensive lymphadenectomy 
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after adjusting for tumor stage, lymph node involvement, age, and sex (p<0.001), but no 
relative risks or confidence intervals were presented.57 However, the potential survival benefit 
provided by more extensive lymphadenectomy in cancer surgery of the esophagus or EGJ has 
been recently challenged. A recent cohort study from Sweden (n=1,044),58 and a study from 
the United Kingdom (n=606),59 both showed similar survival between more and less 
extensive lymphadenectomy after controlling for surgeon volume, T stage, and other potential 
confounding factors. A higher number of removed lymph nodes might cause stage migration 
and biased results suggesting survival benefits following more extensive lymphadenectomy in 
observational studies. The discrepancies in scientific evidence concerning the optimal extent 
of lymphadenectomy are further complicated by the varying definitions for 
lymphadenectomy. 
In summary, although EGJ cancers have a high frequency of lymph node metastasis and the 
presence of such metastasis indicates very poor prognosis, extensive lymphadenectomy does 
not gain much scientific support. Based on the available evidence, a moderately extensive 
lymph node removal seems to be adequate for optimizing the outcomes after EGJ cancer 
surgery.  
 
3.4. Open or minimally invasive surgery? 
Minimally invasive procedures have been gaining popularity in the recent years.60 The first 
laparoscopic gastrectomy was performed in 1991.61 Thereafter, laparoscopic and robot-
assisted gastrectomies for gastric cancer have been examined in several studies, generally 
showing equal surgical and oncological outcomes compared to open techniques.62-64  
A systematic review with 17 retrospective studies compared all minimally invasive (both 
abdominal and thoracic phase, n=494) or hybrid minimally invasive esophagectomy 
(thoracoscopy or laparoscopy, n=386) with open esophagectomy (n=718) for esophageal or 
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EGJ cancer.65 Compared to open procedures, total minimally invasive and hybrid procedures 
had higher lymph node yield (17 nodes and 16 nodes, respectively, vs. 10 nodes in open 
esophagectomy), while the overall 5-year survival was similar between all resection types. 
However, the use of neoadjuvant treatment was greater in total minimally invasive and hybrid 
procedures (54.9% and 43.8% respectively vs. 34.7% in open esophagectomy), thus making 
comparisons regarding survival difficult. No HRQoL data were reported.65 A population-
based study from England showed that minimally invasive surgery (n=1,155) was comparable 
to open surgery (n=6,347) in terms of 30-day mortality and morbidity.66 However, minimally 
invasive procedures required more re-interventions (21.0%) than open procedures (17.6%).66 
No long-term data were available. A recent meta-analysis evaluating 48 studies (1 RCT and 
47 observational studies) compared minimally invasive procedures (thoracoscopy-assisted 
and all minimally invasive procedures, n=4,509) to open surgery (n=9,973) in patients 
undergoing esophagectomy for esophageal or EGJ cancer.67 Results for long-term survival or 
the extent of lymphadenectomy were not available, but minimally invasive esophagectomy 
entailed lower risk of in-hospital mortality (4.6% vs. 3.0%, pooled odds ratio 0.69, 95% 
confidence interval 0.55-0.86) and pulmonary complications (20.4% vs. 17.8%, pooled 
relative risk 0.69, 95% confidence interval 0.61-0.77) compared to open esophagectomy. 
Following minimally invasive esophagectomy, a reduction in incidence of pulmonary 
embolism (pooled odds ratio 0.71, 95% confidence interval 0.51-0.99) and atrial arrhythmias 
(pooled odds ratio 0.79, 95% confidence interval 0.68-0.92) was observed. No differences 
were found regarding the risk of anastomotic leaks or gastric conduit necrosis. However, 
these findings must be interpreted cautiously due to selection bias, as the patients selected for 
minimally invasive esophagectomy were typically low-risk patients with early-stage 
cancers.67 
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The use of a surgical robot with multi-articulated arms and three-dimensional optics allows a 
more precise manipulation of the instruments compared to conventional minimally invasive 
techniques. This is particularly useful in narrow compartments, such as the mediastinum, and 
robot-assisted esophagectomy has been successfully implemented in the treatment of 
esophageal and EGJ cancer, with oncological and surgical outcomes comparable to 
conventional open and minimally invasive resection.68, 69 An advantage is that open 
thoracotomy can be avoided while still enabling a precise mediastinal dissection.68 Yet, 
robotic techniques, as appealing as they may seem, require further testing for all outcomes.20 
On-going RCTs on robotic surgery will hopefully provide such evidence in the future.70 
Taken together, minimally invasive esophagectomy may have comparable oncological 
outcomes and superior in-hospital mortality and pulmonary complication rates compared to 
open procedures in esophageal and EGJ cancer, but RCTs are needed to clarify this due to 
selection bias in the observational studies available. Furthermore, more specific studies on 
outcomes in different Siewert types of EGJ cancer, as well as studies on HRQoL using 
minimally invasive approaches are needed.  
 
3.5. Endoscopic or resectional procedures for early-stage EGJ cancer? 
High-grade dysplasia and early cancers of the EGJ have traditionally been treated with 
conventional surgical resection.71, 72 In recent years, new endoscopic procedures have 
emerged and these are used more and more frequently. Dysplasia and some early-stage (intra-
mucosal) EGJ cancers can be more accurately staged using endoscopic mucosal resection 
(EMR) or endoscopic submucosal dissection (ESD) compared to conventional biopsies, and 
these procedures can sometimes also be used in the treatment of such lesions (Figure 3).73 The 
EMR technique is easier to learn and implement, while ESD can provide a specimen for more 
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accurate histopathological analysis evaluating the need for further surgery. EMR is widely 
used in Western countries and ESD is more common in Japan.73  
 
 
Figure 3. Ligation-assisted endoscopic mucosal resection (EMR) is performed by applying a 
rubber band similar to a variceal ligation band around the affected mucosa. The mucosa is 
then resected by a snare (A). In endoscopic submucosal dissection (ESD) the resection is 
instead done en bloc by using a special electrosurgical knife (B). 
 
Radiofrequency ablation is effective in the treatment of Barrett's esophagus-related low-grade 
dysplasia,74 but has not been extensively studied in early EGJ cancer. The number needed to 
treat to prevent esophageal high-grade dysplasia or esophageal cancer was only 4.0 (95% CI 
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2.8-7.1), according to a recent multi-center RCT.74 Radiofrequency ablation may also be used 
as a complementary treatment of EMR and ESD in EGJ cancer when a columnar-lined 
esophagus is present.75 
Both multiband mucosectomy-EMR and ESD are effective and safe to perform in high-
volume centers.73 A recent systematic review from Japan compared 761 esophageal or EGJ 
lesions treated by EMR and 335 by ESD.73 The tumor recurrence rates were 0.3% for ESD 
and 2.8% for EMR during a mean follow-up of 25-29 months, while EMR was faster to 
perform than ESD (83.3 minutes vs. 36.7 minutes).73 Perforation occurs with both techniques 
in around 1% of patients. Stricture rates were similar, less than 5%, except when 
circumferential EMR (stepwise radical endoscopic resection) was performed (54.7%). 
However, all of the ESD studies in the review were from Japan, where ESD is extensively 
used for the common early-stage gastric cancer and the EMR studies originated from Western 
countries. No RCTs comparing EMR and ESD have been conducted in early EGJ cancer.73  
A large register-based study from the United States compared EMR or ESD (n=1,427) with 
surgical resection (n=3,963) in T1a and T1b esophageal cancer,76 showing a lower 30-day 
mortality (0.5%) in the endoscopically treated patients compared to the surgical group (3.5%). 
However, the 3-year survival rates were lower in the endoscopy treatment group (76.5% vs. 
87.6%, respectively). The presence of lymph node metastases in the surgically treated patients 
was 5.0% in patients staged T1a (0.5% with mucosal lesions <2cm) and 16.6% in patients 
staged T1b (8.9% with mucosal lesions <2cm), which probably contributes to the lower 3-
year survival in the endoscopic treatment group.76 
Taken together, the mainstay treatment for early-stage EGJ cancers (T1) should remain 
resectional surgery providing the patient is deemed healthy and fit enough to undergo such 
surgery. In non-surgical candidates, both EMR and ESD may be used as safe and effective 
alternatives to surgery in intra-mucosal EGJ cancers, supported by radiofrequency ablation 
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when Barrett’s esophagus is present. Large RCTs are needed to better define the role of 
endoscopic treatment for early EGJ cancer.  
 
4. Discussion and conclusions 
Studies investigating potential differences in mortality and morbidity between gastrectomy vs. 
esophagectomy, transhiatal vs. transthoracic approach, and minimally invasive 
esophagectomy vs. open surgery in adenocarcinoma of the EGJ have failed to show any clear 
differences between these approaches in overall survival. However, the existing literature is 
very limited and there is a need for well-designed RCTs. The gastrectomy approach might 
provide better HRQoL outcomes compared to esophagectomy, but the literature is too limited 
to draw firm conclusions. Transthoracic esophagectomy allows more complete 
lymphadenectomy of the mediastinum compared to transhiatal esophagectomy, but this does 
not seem to improve the survival and may rather increase pulmonary complications and 
prolong hospital stay. Any survival benefits of extensive lymphadenectomy remains to be 
proven. Current evidence would indicate a moderate lymphadenectomy. Minimally invasive 
surgery has emerged as a promising approach, which might potentially reduce the risk of 
postoperative complications and improve HRQoL compared to open techniques, but large 
RCTs are required to evaluate any such benefit. In early-stage cancers, resectional surgery 
remains the recommended therapy, but EMR and ESD are safe alternatives in patients not 
eligible for resection, but large RCTs are needed. 
More focused research with larger patient samples is required to elucidate the differences in 
HRQoL between surgical approaches, as well as the optimal extent of lymphadenectomy. The 
available evidence does not make it possible to strongly recommend any of the well-
established surgical procedures over the others in the treatment of EGJ cancer. Thus, the 
choice of surgical approach should be guided by the preference and experience of the 
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institutions and surgeons. Based on these scarce data, transthoracic or minimally invasive 
esophagectomy would be the treatment of choice for type I tumors, transhiatal esophagectomy 
or gastrectomy for type II tumors and extended gastrectomy for type III tumors to reduce the 
postoperative pulmonary complications and improve the quality of life after surgery. 
Extensive lymphadenectomy remains questionable, and we rather suggest a moderate 
locoregional lymphadenectomy without the harvest of distant lymph nodes or splenectomy. 
For T1 EGJ tumors, surgical resection remains the mainstay therapy, while endoscopic 
procedures should be used in patients ineligible for such surgery.  
In conclusion, there is a great need for well-designed large RCTs to forward our knowledge in 
the surgical treatment of EGJ cancer. These trials should elucidate not only the oncological 
and postoperative outcomes, but also health-related quality of life perceived by the cancer 
patient. 
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